Trulieve is projected to report Q2 2026 revenue of $284.08 million and EPS of $0.06, with the current share price of $8.60 representing substantial upside toward the $18.18 analyst target.
The central story for investors is the transition to Schedule III federal status, which is expected to eliminate punitive 280E tax burdens and boost net profitability.
This report follows a strong first quarter where the company returned to positive net income and generated $42 million in free cash flow. Analysts are also hyper-focused on the company's preparations for the upcoming Florida adult-use legalization vote, which could transform its core market.